Recruiting
Papulopustular rosacea
RecruitingEfficacy and safety of remibrutinib (LOU064) in adult patients with papulopustular rosacea: a randomized, double‑blind, placebo‑controlled Phase 2 trial
Investigational
Efficacy and safety of remibrutinib (LOU064) in adult patients with papulopustular rosacea: a randomized, double‑blind, placebo‑controlled Phase 2 trial
Investigational
- Disease:Papulopustular rosacea
- Substances:Remibrutinib
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Remibrutinib
- Sponsor:Novartis Pharma AG



